Piper Sandler analyst David Westenberg raised the firm’s price target on Quest Diagnostics (DGX) to $180 from $165 and keeps a Neutral rating on the shares following quarterly results. The firm highlights the company’s growth into higher margin and growth areas of testing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Reports Strong Q4 Revenue Growth
- Quest Diagnostics price target raised to $182 from $172 at Truist
- Quest Diagnostics price target raised to $189 from $184 at Baird
- Quest Diagnostics price target raised to $175 from $168 at Barclays
- Quest Diagnostics Reports Strong Growth and Future Confidence
Questions or Comments about the article? Write to editor@tipranks.com